<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-050866</identifier>
<setSpec>1138-3593</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Coronary risk in a Mediterranean hypercholesterolemic population: do we over estimate or under estimate the risk?</dc:title>
<dc:description xml:lang="en">OBJECTIVES. To determine concordance in the coronary risk (CR) score between Framingham and REGICOR charts and the therapeutic consequences in following the hyperlipidemia guideline of Institut Català de la Salut for high-level coronary risk with 20% Framingham function (G-ICS-F), 20% REGICOR function (G-ICS-R 20%) or 10% REGICOR function (G-ICS-R-10%). METHOD. Descriptive cross-sectional study in a Primary Health Care Center. Four hundred and thirteen patients with hypercholesterolemia and no history of ischemic heart disease were enrolled. Age, gender, family history of coronary disease, smoking habits, hypertension, systolic blood pressure and complete lipid profile before treatment were studied. Coronary risk was estimated by means of Framingham and REGICOR functions. Theoretical indications of lipid-lowering treatment were analyzed. RESULTS. There is strong disagreement between coronary risk calculated with Framingham and REGICOR charts (kappa coefficient 0.066). Lipid-lowering treatment is indicated in 22.8% patients with G-ICS-F-10,4% with G-ICS-R-20% and 20.8% with G-ICSR-10%. The agreement of recommended treatment between G-ICS-F and G-ICS-R-20% is moderate (kappa 0.535), while between G-ICS-F and G-ICS-R-10% is good (kappa 0.688). There is no agreement in two groups: 4.3% without treatment by G-ICS-F and treated by G-ICS-R-10% and the 6.3% treated by G-ICS-F and without treatment by G-ICS-R-10% CONCLUSIONS. The estimation of coronary risk may be either overestimates (Framingham) or underestimates (REGICOR) in our patients. We conclude that a reasonable option may be to accept G-ICS-R-10% in our therapy guideline to properly estimate the coronary risk. Furthermore, it will reduce the number of patients under treatment with the consequent drug-financial impact</dc:description>
<dc:creator>Valero García, C</dc:creator>
<dc:creator>Asenjo Vázquez, C</dc:creator>
<dc:creator>Ponce de León Roca, M</dc:creator>
<dc:creator>Otero Bermejo, O</dc:creator>
<dc:creator>Ratia López, I</dc:creator>
<dc:creator>Corio Andújar, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVOS. Determinar la concordancia en el cálculo de riesgo coronario (RC) entre la tabla de Framingham y la tabla REGICOR y las implicaciones terapéuticas al aplicar la guía de hipercolesterolemia del Institut Català de la Salut con el dintel de RC alto del 20% de Framingham (G-ICS-F), con el 20% de REGICOR (G-ICS-R20%) y con el 10% de REGICOR (G-ICS-R10%). MÉTODO. Estudio descriptivo transversal en un Área Básica Urbana. Participan 413 pacientes hipercolesterolémicos sin cardiopatía isquémica. Se analizaron edad, sexo, antecedentes familiares de cardiopatía isquémica, tabaquismo, hipertensión arterial (HTA), presión arterial sistólica (PAS) y perfil lipídico completo previo al tratamiento. Se calculó el RC usando las tablas de Framingham y de REGICOR y se analizaron las indicaciones terapéuticas. RESULTADOS. La concordancia entre el RC calculado con Framingham y REGICOR es muy débil (kappa = 0,066). Aplicando la G-ICS-F tratamos farmacológicamente al 22,8%, con la G-ICSR20% al 10,4% y con la G-ICS-R10% al 20,8%. La concordancia de la intervención terapéutica entre G-ICS-F y G-ICS-R20% es moderada (kappa = 0,535), siendo buena entre G-ICS-F y G-ICS-R10% (kappa = 0,688). Presentan discordancia dos grupos: el 4,3% sin tratamiento según G-ICS-F y con tratamiento G-ICS-R10% y el 6,3% con tratamiento según G-ICS-F y sin tratamiento G-ICS-R10%. CONCLUSIONES. El cálculo del RC con REGICOR puede infraestimar el riesgo de nuestra población y con Framingham sobreestimarlo. Nos parece un opción razonable aceptar como alto el RC &gt; 10% con REGICOR en nuestra guía terapéutica para estimar el riesgo de forma correcta, reduciendo ligeramente el número de tratamientos a aplicar, con el consiguiente impacto fármaco-económico</dc:description>
<dc:source>SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.);32(10): 479-483, dic. 2006. tab, graf</dc:source>
<dc:identifier>ibc-050866</dc:identifier>
<dc:title xml:lang="es">Riesgo coronario en una población hipercolesterolémica mediterránea: ¿sobreestimamos o infraestimamos el riesgo?</dc:title>
<dc:subject>^d3343^s22062</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d3343^s22027</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d14904</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d28596</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d13411</dc:subject>
<dc:subject>^d32048^s22045</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d7117^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200612</dc:date>
</metadata>
</record>
</ibecs-document>
